Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Rohit Loomba(University of California, San Diego), Erin Morgan(Ionis Pharmaceuticals (United States)), Lynnetta M. Watts(Ionis Pharmaceuticals (United States)), Shuting Xia(Ionis Pharmaceuticals (United States)), Lisa A. Hannan(Ionis Pharmaceuticals (United States)), Richard S. Geary(Ionis Pharmaceuticals (United States)), Brenda F. Baker(Ionis Pharmaceuticals (United States)), Sanjay Bhanot(Ionis Pharmaceuticals (United States))
˜The œLancet. Gastroenterology & hepatology
June 15, 2020
Cited by 117

Abstract


Related Papers

No related papers found

Powered by citation graph analysis